SCHEMBL29236

SCHEMBL29236

CC(C)[Si](C(C)C)(C(C)C)n1ccc2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 5/20 0.41
CDK4 P11802 4/20 0.41
CCND1 P24385 4/20 0.41
NOTUM Q6P988 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.38
PBRM1 Q86U86 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36
BIRC5 O15392 1/20 0.35
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
OPRK1 P41145 1/20 0.35
OPRL1 P41146 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15024920 0.78 HTR6 (0.46)
SCHEMBL9804292 0.77 CDK4 (0.45) SLC6A2CDK4CCND1NOTUMSMN1; SMN2
SCHEMBL29479212 0.77 CDK4 (0.45) SLC6A2CDK4CCND1NOTUMSMN1; SMN2
SCHEMBL29479213 0.77 CDK4 (0.45) SLC6A2CDK4CCND1NOTUMSMN1; SMN2
SCHEMBL16937932 0.76 HTR2A (0.49) HTR2AHTR2CCYP1A2OPRD1
SCHEMBL28979 0.76 HTR2A (0.49) SLC6A2CDK4CCND1HTR2AHTR2C
SCHEMBL12544395 0.74 HTR2C (0.50) SLC6A2HTR2AHTR2C
SCHEMBL917628 0.74 PRKCI (0.41) SLC6A2SMN1; SMN2HTR2AHTR2CCYP3A4
SCHEMBL30949143 0.74 HTR2A (0.50) SLC6A2CDK4CCND1HTR2AHTR2C
SCHEMBL30967900 0.74 HTR2A (0.50) SLC6A2HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111048415-B Selective etching liquid composition and preparation method and application thereof 上海新阳半导体材料股份有限公司 2023-03-14 CN claimed
EP-3458442-B1 SYNTHESIS OF 6-ARYL-4-AMINOPICOLINATES AND 2-ARYL-6-AMINOPYRIMIDINE-4-CARBOXYLATES BY DIRECT SUZUKI COUPLING CORTEVA AGRISCIENCE LLC (US) 2022-12-28 EP claimed
CN-111048415-A Selective etching liquid composition and preparation method and application thereof 上海新阳半导体材料股份有限公司 2020-04-21 CN claimed
US-12351556-B2 Pyridin-2(1H)one derivatives, their preparation and their use for the treatment of pain INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2025-07-08 US disclosed
CN-111048415-B Selective etching liquid composition and preparation method and application thereof 上海新阳半导体材料股份有限公司 2023-03-14 CN disclosed
US-11572434-B2 Curable composition, method for producing same, and article using same DAIKIN INDUSTRIES, LTD. (JP) 2023-02-07 US disclosed
US-20220363643-A1 NOVEL PYRIDIN-2(1H)ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF PAIN CENTRE HOSPITALIER UNIVERSITAIRE DE CLERMONT-FD (FR) 2022-11-17 US disclosed
WO-2022232233-A1 INDOLEAZETIDINES AND THEIR USE IN METHODS FOR TREATING 5-HT2 RESPONSIVE CONDITIONS ELEUSIS THERAPEUTICS US, INC. (US) 2022-11-03 WO disclosed
EP-4037770-A1 NOVEL PYRIDIN-2(1H)ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF PAIN INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2022-08-10 EP disclosed
US-11239498-B2 Electrolytic solution and lithium-ion battery CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED (CN) 2022-02-01 US disclosed
CN-110391457-B Electrolyte and lithium ion battery 宁德时代新能源科技股份有限公司 2021-11-02 CN disclosed
EP-0574174-B1 Angiotensin II antagonists LILLY CO ELI (US) 2003-08-13 EP disclosed
WO-2000000490-A2 5-HT1F AGONISTS ELI LILLY AND COMPANY (US) 2000-01-06 WO disclosed
US-5693633-A Angiotensin II antagonists ELI LILLY AND COMPANY (US) 1997-12-02 US disclosed
US-5612360-A AROMATIC N-HETEROCYCLIC COMPOUNDS AS HYPOTENSIVE AGENTS WITH ACID GROUPS, SULFONYLCARBOXAMIDES OR TETRAZOLE GROUPS ELI LILLY AND COMPANY (US) 1997-03-18 US disclosed
US-5569768-A USEFUL IN TREATING HYPERTENSION, CONGESTIVE HEART FAILURE, GLAUCOMA AND RENAL INSUFFICIENCY ELI LILLY AND COMPANY (US) 1996-10-29 US disclosed
US-5556981-A Angiotensin II antagonist intermediates ELI LILLY AND COMPANY (US) 1996-09-17 US disclosed
WO-1995007910-A1 ANTIVIRAL INDOLE DERIVATIVES THE WELLCOME FOUNDATION LIMITED (GB) 1995-03-23 WO disclosed
EP-0636129-A1 INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS Pfizer Limited (GB) 1995-02-01 EP disclosed
EP-0574174-A2 Angiotensin II antagonists ELI LILLY AND COMPANY (US) 1993-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220363643-A1 NOVEL PYRIDIN-2(1H)ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF PAIN P2RX3, OPRL1, P2RX6 SLC6A2 1298/4885CDK4 855/4885CCND1 3662/4885
US-12351556-B2 Pyridin-2(1H)one derivatives, their preparation and their use for the treatment of pain P2RX3, P2RX6, P2RX4 SLC6A2 918/4885CDK4 799/4885CCND1 3331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.